...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Top-Line Data Expected September 2019 for BETonMACE Phase 3 Cardiovascular Outcomes Trial for Apabetalone


BREAKING: Spyder Cannabis Enters into MOU with HighBreed Growth Corp. for a Proposed Reverse Takeover Transaction

  • Through its Israeli subsidiary HighBreed Growth Ltd., is building a cannabis cultivation greenhouses facilities in Israel with a total planned size of 500,000 square feet.
  • HBGC has signed domestic sale contract with an entity to purchase its production capacity
  • Israeli government announced that it would approve cannabis for export in 2019, and regulations are expected to be enacted in the 2nd quarter of 2020 to authorize export

Spdr logo large

Hub On AGORACOMRead Release

Message: AGM 2018 - Masila Notes

This is I think where I got the idea that patients might have the option to continue taking Apabetalone after the trial wrapped up....from masila's notes from Sept's AGM, the post to which I am replying....here's the relevant section that probably led me to think this:  

Apparently all patients interviewed want to stay on the treatment.  Some have been on close to 36 months.  That speaks volumes to me! 

New Message
Please login to post a reply